MedPage Today (5/12, George) reports a study found that “treating early Alzheimer’s disease patients with lecanemab (Leqembi) was feasible and most patients tolerated the drug well.” Researchers observed that “infusion-related reactions occurred in 37% of 234 Alzheimer’s patients treated with lecanemab and typically were mild.” In addition, “amyloid-related imaging abnormalities (ARIA) emerged in 42 of 194 people (22%) who received at least four lecanemab infusions and had at least one MRI.” Researchers say “most ARIA cases were asymptomatic (74%) and radiographically mild (62%).” They noted that “patients with mild dementia at baseline had a 15-fold higher rate of symptomatic ARIA compared with those with mild cognitive impairment or very mild dementia.” The study was published in JAMA Neurology. (SOURCE: APA Headlines)